retatrutide phase 2 trial obesity nejm 2023 Research Guide: What the Data Reported (2026) Retatrutide Phase 2 NEJM Trial:

Amycretin (Zenagamtide) This is Novo's next-generation molecule and potentially their most exciting one yet

Even food companies without much exposure to GLP-1 users are broadening their portfolios to reach them

You can explore our approach to weight management at Check Your Eligibility If you want to learn whether GLP-1 treatment is appropriate for your health needs and receive personalized guidance on nutrition and exercise during treatment, you can start by completing Mochis eligibility questionnaire

While these medications have marketing authorisations for specific indications, NHS access is governed by NICE technology appraisals, which set narrower eligibility criteria than the marketing authorisation